Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2013

Open Access 01-02-2013 | Epidemiology

Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study

Authors: Roberto Pastor-Barriuso, Nieves Ascunce, María Ederra, Nieves Erdozáin, Alberto Murillo, José E. Alés-Martínez, Marina Pollán

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Login to get access

Abstract

The Gail model for predicting the absolute risk of invasive breast cancer has been validated extensively in US populations, but its performance in the international setting remains uncertain. We evaluated the predictive accuracy of the Gail model in 54,649 Spanish women aged 45–68 years who were free of breast cancer at the 1996–1998 baseline mammographic examination in the population-based Navarre Breast Cancer Screening Program. Incident cases of invasive breast cancer and competing deaths were ascertained until the end of 2005 (average follow-up of 7.7 years) through linkage with population-based cancer and mortality registries. The Gail model was tested for calibration and discrimination in its original form and after recalibration to the lower breast cancer incidence and risk factor prevalence in the study cohort, and compared through cross-validation with a Navarre model fully developed from this cohort. The original Gail model overpredicted significantly the 835 cases of invasive breast cancer observed in the cohort (ratio of expected to observed cases 1.46, 95 % CI 1.36–1.56). The recalibrated Gail model was well calibrated overall (expected-to-observed ratio 1.00, 95 % CI 0.94–1.07), but it tended to underestimate risk for women in low-risk quintiles and to overestimate risk in high-risk quintiles (P = 0.01). The Navarre model showed good cross-validated calibration overall (expected-to-observed ratio 0.98, 95 % CI 0.92–1.05) and in different cohort subsets. The Navarre and Gail models had modest cross-validated discrimination indexes of 0.542 (95 % CI 0.521–0.564) and 0.544 (95 % CI 0.523–0.565), respectively. Although the original Gail model cannot be applied directly to populations with different underlying rates of invasive breast cancer, it can readily be recalibrated to provide unbiased estimates of absolute risk in such populations. Nevertheless, its limited discrimination ability at the individual level highlights the need to develop extended models with additional strong risk factors.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef
2.
go back to reference Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548PubMedCrossRef Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS (1999) Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 91:1541–1548PubMedCrossRef
3.
go back to reference Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358–366PubMedCrossRef Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93:358–366PubMedCrossRef
4.
go back to reference Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA (2007) Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 99:1695–1705PubMedCrossRef Chlebowski RT, Anderson GL, Lane DS, Aragaki AK, Rohan T, Yasmeen S, Sarto G, Rosenberg CA, Hubbell FA (2007) Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst 99:1695–1705PubMedCrossRef
5.
go back to reference Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV Jr, Park Y, Schatzkin A, Visvanathan K, Pfeiffer RM (2010) Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol 28:2411–2417PubMedCrossRef Schonfeld SJ, Pee D, Greenlee RT, Hartge P, Lacey JV Jr, Park Y, Schatzkin A, Visvanathan K, Pfeiffer RM (2010) Effect of changing breast cancer incidence rates on the calibration of the Gail model. J Clin Oncol 28:2411–2417PubMedCrossRef
6.
go back to reference Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG (1994) Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86:620–625PubMedCrossRef Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG (1994) Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 86:620–625PubMedCrossRef
7.
go back to reference Pankratz VS, Hartmann LC, Degnim AC, Vierkant RA, Ghosh K, Vachon CM, Frost MH, Maloney SD, Reynolds C, Boughey JC (2008) Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol 26:5374–5379PubMedCrossRef Pankratz VS, Hartmann LC, Degnim AC, Vierkant RA, Ghosh K, Vachon CM, Frost MH, Maloney SD, Reynolds C, Boughey JC (2008) Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol 26:5374–5379PubMedCrossRef
8.
go back to reference Meads C, Ahmed I, Riley RD (2012) A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat 132:365–377PubMedCrossRef Meads C, Ahmed I, Riley RD (2012) A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance. Breast Cancer Res Treat 132:365–377PubMedCrossRef
9.
go back to reference Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRef Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRef
10.
go back to reference Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381–2391PubMedCrossRef Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, McTiernan A, Robbins J, Johnson KC, Martin LW, Winquist E, Sarto GE, Garber JE, Fabian CJ, Pujol P, Maunsell E, Farmer P, Gelmon KA, Tu D, Richardson H (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381–2391PubMedCrossRef
11.
go back to reference Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235–3258PubMedCrossRef Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM (2009) American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 27:3235–3258PubMedCrossRef
12.
go back to reference Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40:807–814PubMedCrossRef Amir E, Evans DG, Shenton A, Lalloo F, Moran A, Boggis C, Wilson M, Howell A (2003) Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 40:807–814PubMedCrossRef
13.
go back to reference Boyle P, Mezzetti M, La Vecchia C, Franceschi S, Decarli A, Robertson C (2004) Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Eur J Cancer Prev 13:183–191PubMedCrossRef Boyle P, Mezzetti M, La Vecchia C, Franceschi S, Decarli A, Robertson C (2004) Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. Eur J Cancer Prev 13:183–191PubMedCrossRef
14.
go back to reference Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH (2006) Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation into Cancer and Nutrition cohort. J Natl Cancer Inst 98:1686–1693PubMedCrossRef Decarli A, Calza S, Masala G, Specchia C, Palli D, Gail MH (2006) Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation into Cancer and Nutrition cohort. J Natl Cancer Inst 98:1686–1693PubMedCrossRef
15.
go back to reference Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M (2010) Cancer screening in Spain. Ann Oncol 21(Suppl 3):iii43–iii51PubMedCrossRef Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M (2010) Cancer screening in Spain. Ann Oncol 21(Suppl 3):iii43–iii51PubMedCrossRef
16.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, Lyon. http://globocan.iarc.fr. Accessed Dec 2012 Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC CancerBase No. 10. International Agency for Research on Cancer, Lyon. http://​globocan.​iarc.​fr. Accessed Dec 2012
17.
go back to reference Ascunce N, Ederra M, Barcos A, Zubizarreta R, Fernández AB, Casamitjana M (2007) Situación del cribado de cáncer de mama en España: características y principales resultados de los programas existentes. In: Castells X, Sala M, Ascunce N, Salas D, Zubizarreta R, Casamitjana M (eds) Descripción del cribado del cáncer en España. Proyecto DESCRIC. Ministerio de Sanidad y Consumo, Madrid, pp 31–73 Ascunce N, Ederra M, Barcos A, Zubizarreta R, Fernández AB, Casamitjana M (2007) Situación del cribado de cáncer de mama en España: características y principales resultados de los programas existentes. In: Castells X, Sala M, Ascunce N, Salas D, Zubizarreta R, Casamitjana M (eds) Descripción del cribado del cáncer en España. Proyecto DESCRIC. Ministerio de Sanidad y Consumo, Madrid, pp 31–73
18.
go back to reference Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg
19.
go back to reference Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, Sánchez-Pérez MJ, Chirlaque MD, Larrañaga N, Martínez-Cobo R, Tobalina MC, Vidal E, Marcos-Gragera R, Mateos A, Garau I, Rojas-Martín MD, Jiménez R, Torrella-Ramos A, Perucha J, Pérez-de-Rada ME, González S, Rabanaque MJ, Borràs J, Navarro C, Hernández E, Izquierdo A, López-Abente G, Martínez C (2009) Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst 101:1584–1591PubMedCrossRef Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, Sánchez-Pérez MJ, Chirlaque MD, Larrañaga N, Martínez-Cobo R, Tobalina MC, Vidal E, Marcos-Gragera R, Mateos A, Garau I, Rojas-Martín MD, Jiménez R, Torrella-Ramos A, Perucha J, Pérez-de-Rada ME, González S, Rabanaque MJ, Borràs J, Navarro C, Hernández E, Izquierdo A, López-Abente G, Martínez C (2009) Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst 101:1584–1591PubMedCrossRef
20.
go back to reference Ascunce N, Moreno-Iribas C, Barcos-Urtiaga A, Ardanaz E, Ederra-Sanz M, Castilla J, Egüés N (2007) Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. J Med Screen 14:14–20PubMedCrossRef Ascunce N, Moreno-Iribas C, Barcos-Urtiaga A, Ardanaz E, Ederra-Sanz M, Castilla J, Egüés N (2007) Changes in breast cancer mortality in Navarre (Spain) after introduction of a screening programme. J Med Screen 14:14–20PubMedCrossRef
22.
go back to reference Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (2007) Cancer incidence in five continents, vol IX. International Agency for Research on Cancer, Lyon Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P (2007) Cancer incidence in five continents, vol IX. International Agency for Research on Cancer, Lyon
23.
go back to reference Benichou J, Gail MH (1990) Estimates of absolute cause-specific risk in cohort studies. Biometrics 46:813–826PubMedCrossRef Benichou J, Gail MH (1990) Estimates of absolute cause-specific risk in cohort studies. Biometrics 46:813–826PubMedCrossRef
24.
go back to reference Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, London Efron B, Tibshirani RJ (1993) An introduction to the bootstrap. Chapman and Hall, London
25.
go back to reference Gail MH, Pfeiffer RM (2005) On criteria for evaluating models of absolute risk. Biostatistics 6:227–239PubMedCrossRef Gail MH, Pfeiffer RM (2005) On criteria for evaluating models of absolute risk. Biostatistics 6:227–239PubMedCrossRef
26.
go back to reference Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109–2123PubMedCrossRef Pencina MJ, D’Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109–2123PubMedCrossRef
27.
go back to reference Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674PubMedCrossRef Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674PubMedCrossRef
28.
go back to reference Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, John EM, Hubbell FA, Yasmeen S, Katki HA (2012) Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat 132:347–353PubMedCrossRef Banegas MP, Gail MH, LaCroix A, Thompson B, Martinez ME, Wactawski-Wende J, John EM, Hubbell FA, Yasmeen S, Katki HA (2012) Evaluating breast cancer risk projections for Hispanic women. Breast Cancer Res Treat 132:347–353PubMedCrossRef
29.
go back to reference Chay WY, Ong WS, Tan PH, Jie Leo NQ, Ho GH, Wong CS, Chia KS, Chow KY, Tan M Sr, Ang P Sr (2012) Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res 14:R19PubMedCrossRef Chay WY, Ong WS, Tan PH, Jie Leo NQ, Ho GH, Wong CS, Chia KS, Chow KY, Tan M Sr, Ang P Sr (2012) Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women. Breast Cancer Res 14:R19PubMedCrossRef
31.
go back to reference Swan J, Breen N, Graubard BI, McNeel TS, Blackman D, Tangka FK, Ballard-Barbash R (2010) Data and trends in cancer screening in the United States: results from the 2005 National Health Interview Survey. Cancer 116:4872–4881PubMedCrossRef Swan J, Breen N, Graubard BI, McNeel TS, Blackman D, Tangka FK, Ballard-Barbash R (2010) Data and trends in cancer screening in the United States: results from the 2005 National Health Interview Survey. Cancer 116:4872–4881PubMedCrossRef
32.
go back to reference Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef Flegal KM, Carroll MD, Ogden CL, Curtin LR (2010) Prevalence and trends in obesity among US adults, 1999–2008. JAMA 303:235–241PubMedCrossRef
33.
go back to reference Ortiz-Moncada R, Álvarez-Dardet C, Miralles-Bueno JJ, Ruíz-Cantero MT, dal Re-Saavedra MA, Villar-Villalba C, Pérez-Farinós N, Serra-Majem L (2011) Social determinants of overweight and obesity in Spain in 2006. Med Clin (Barc) 137:678–684CrossRef Ortiz-Moncada R, Álvarez-Dardet C, Miralles-Bueno JJ, Ruíz-Cantero MT, dal Re-Saavedra MA, Villar-Villalba C, Pérez-Farinós N, Serra-Majem L (2011) Social determinants of overweight and obesity in Spain in 2006. Med Clin (Barc) 137:678–684CrossRef
34.
go back to reference Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53PubMedCrossRef Hersh AL, Stefanick ML, Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47–53PubMedCrossRef
35.
go back to reference Benet Rodríguez M, Carvajal García-Pando A, García del Pozo J, Álvarez Requejo A, Vega Alonso T (2002) Hormonal replacement therapy in Spain. Med Clin (Barc) 119:4–8 Benet Rodríguez M, Carvajal García-Pando A, García del Pozo J, Álvarez Requejo A, Vega Alonso T (2002) Hormonal replacement therapy in Spain. Med Clin (Barc) 119:4–8
36.
go back to reference Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat 72:107–115PubMedCrossRef Clavel-Chapelon F, Gerber M (2002) Reproductive factors and breast cancer risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat 72:107–115PubMedCrossRef
37.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399CrossRef
38.
go back to reference Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846PubMedCrossRef Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91:1829–1846PubMedCrossRef
39.
go back to reference Gail MH (2011) Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 30:1090–1104PubMedCrossRef Gail MH (2011) Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med 30:1090–1104PubMedCrossRef
40.
go back to reference Gail MH (2008) Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100:1037–1041PubMedCrossRef Gail MH (2008) Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 100:1037–1041PubMedCrossRef
41.
go back to reference Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, Thun MJ, Cox DG, Hankinson SE, Kraft P, Rosner B, Berg CD, Brinton LA, Lissowska J, Sherman ME, Chlebowski R, Kooperberg C, Jackson RD, Buckman DW, Hui P, Pfeiffer R, Jacobs KB, Thomas GD, Hoover RN, Gail MH, Chanock SJ, Hunter DJ (2010) Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362:986–993PubMedCrossRef Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, Thun MJ, Cox DG, Hankinson SE, Kraft P, Rosner B, Berg CD, Brinton LA, Lissowska J, Sherman ME, Chlebowski R, Kooperberg C, Jackson RD, Buckman DW, Hui P, Pfeiffer R, Jacobs KB, Thomas GD, Hoover RN, Gail MH, Chanock SJ, Hunter DJ (2010) Performance of common genetic variants in breast-cancer risk models. N Engl J Med 362:986–993PubMedCrossRef
42.
go back to reference Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K (2012) Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 14:R25PubMedCrossRef Darabi H, Czene K, Zhao W, Liu J, Hall P, Humphreys K (2012) Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res 14:R25PubMedCrossRef
43.
go back to reference Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98:1215–1226PubMedCrossRef Chen J, Pee D, Ayyagari R, Graubard B, Schairer C, Byrne C, Benichou J, Gail MH (2006) Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 98:1215–1226PubMedCrossRef
44.
go back to reference Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ III, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237PubMedCrossRef Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ III, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353:229–237PubMedCrossRef
45.
go back to reference Schisterman EF, Faraggi D, Reiser B, Trevisan M (2001) Statistical inference for the area under the receiver operating characteristic curve in the presence of random measurement error. Am J Epidemiol 154:174–179PubMedCrossRef Schisterman EF, Faraggi D, Reiser B, Trevisan M (2001) Statistical inference for the area under the receiver operating characteristic curve in the presence of random measurement error. Am J Epidemiol 154:174–179PubMedCrossRef
46.
go back to reference Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef Murff HJ, Spigel DR, Syngal S (2004) Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 292:1480–1489PubMedCrossRef
Metadata
Title
Recalibration of the Gail model for predicting invasive breast cancer risk in Spanish women: a population-based cohort study
Authors
Roberto Pastor-Barriuso
Nieves Ascunce
María Ederra
Nieves Erdozáin
Alberto Murillo
José E. Alés-Martínez
Marina Pollán
Publication date
01-02-2013
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-013-2428-y

Other articles of this Issue 1/2013

Breast Cancer Research and Treatment 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine